Philippe Tessier studied at Laval University, the John Curtin School of Medical Research (Australian National University) and the University of Adelaide, followed by a post-doctoral fellowship at the Imperial Cancer Research Fund (United Kingdom). He has been a researcher at the Centre de recherche du CHU de Québec – Laval University since 1999, and a professor at the Department of Microbiology-Infectiology and Immunology of the Laval University School of Medicine.
Professor Tessier studies the biological activities of the proteins S100A8 and S100A9, two small proteins expressed by neutrophils, monocytes, and activated endothelial and epithelial cells. These proteins are secreted during inflammation and activate the immune response. His research indicates that S100A8 and S100A9 have opposite functions: S100A8 is anti-inflammatory and inhibits myeloid cell differentiation, while S100A9 is pro-inflammatory and induces the differentiation of precursors of neutrophils and monocytes. He studies the roles of these proteins in autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease, in immune responses to solid tumors, and in the differentiation of leukemia cells.
Auto-inflammatory diseases are monogenic orphan diseases (<10,000 cases per syndrome worldwide) usually caused by defects in the genes regulating innate immunity. These diseases are characterized by recurrent, unprovoked inflammation (fever, abdominal pain, rash, arthralgia). High plasma concentrations of S100A8 and S100A9 are often found in patients with auto-inflammatory diseases. In collaboration with Professor Martin Pelletier and Dr. Anne-Laure Chetaille, Prof. Tessier is currently studying the roles of S100A8 and S100A9 in these diseases, to develop a diagnostic test to facilitate the treatment of these patients.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB(1.).Journal Article
PLoS ONE, 8 (8), pp. e72138, 2013.
Impact of neutrophil-secreted myeloid related proteins 8 and 14 (MRP 8/14) on leishmaniasis progression.Journal Article
PLoS Negl Trop Dis, 7 (9), pp. e2461, 2013, ISSN: 1935-2727.
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria.Journal Article
Science, 336 (6086), pp. 1321-5, 2012, ISSN: 0036-8075.
An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis.Journal Article
PLoS ONE, 7 (9), pp. e45478, 2012.
Damage-associated molecular pattern S100A9 increases bactericidal activity of human neutrophils by enhancing phagocytosis.Journal Article
J Immunol, 186 (6), pp. 3622-31, 2011, ISSN: 0022-1767.
Induction of neutrophil degranulation by S100A9 via a MAPK-dependent mechanism.Journal Article
J Leukoc Biol, 87 (5), pp. 905-14, 2010, ISSN: 0741-5400.
Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption.Journal Article
Blood, 114 (8), pp. 1633-44, 2009, ISSN: 0006-4971.
Myeloid-related proteins rapidly modulate macrophage nitric oxide production during innate immune response.Journal Article
J Immunol, 181 (5), pp. 3595-601, 2008, ISSN: 0022-1767.
Blockade of antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the alveoli in streptococcal pneumonia.Journal Article
J Immunol, 180 (5), pp. 3366-74, 2008, ISSN: 0022-1767.
Localization of S100A8 and S100A9 expressing neutrophils to spinal cord during peripheral tissue inflammation.Journal Article
Pain, 134 (1-2), pp. 216-31, 2008, ISSN: 0304-3959.
- Biology of S100A8 and S100A9 proteins in Human Acute Myeloid Leukemia, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2024-09-30
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Recently finished projects
- Centre de recherche en arthrite de l'Université Laval, Subvention, Institutionnel - BDR, BDR - Entités de recherche en émergence, from 2019-01-01 to 2020-01-31
- Immunosuppressive function of S100A8 in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-07-01 to 2019-06-30
- The characterization of MICL, a novel negative regulator of the immune response in arthritis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30